EA201590396A1 - Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения - Google Patents
Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и примененияInfo
- Publication number
- EA201590396A1 EA201590396A1 EA201590396A EA201590396A EA201590396A1 EA 201590396 A1 EA201590396 A1 EA 201590396A1 EA 201590396 A EA201590396 A EA 201590396A EA 201590396 A EA201590396 A EA 201590396A EA 201590396 A1 EA201590396 A1 EA 201590396A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- composition containing
- sterehemistry
- dynucleotides
- cyclic purine
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
Abstract
Задачей настоящего изобретения является получение новых и высокоактивных иммуностимуляторов, представляющих собой циклические динуклеотиды (ЦДН), которые активируют ДК через недавно обнаруженный цитоплазматический рецептор, известный как STING (стимулятор генов интерферонов). В частности, ЦДН согласно настоящему изобретению предложены в форме композиции, содержащей один или более циклических пуриновых динуклеотидов, которые индуцируют STING-зависимую активацию TBK1, при этом циклические пуриновые динуклеотиды, присутствующие в указанной композиции, представляют собой, по существу, чистые Rp,Rp или Rp,Sp-стереоизмеры и, в частности, по существу, чистые Rp,Rp или Rp,Sp-диастереомеры тиофосфатных ЦДН.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261737006P | 2012-12-13 | 2012-12-13 | |
US201361790514P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/075189 WO2014093936A1 (en) | 2012-12-13 | 2013-12-13 | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201590396A1 true EA201590396A1 (ru) | 2015-12-30 |
Family
ID=50935019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201590396A EA201590396A1 (ru) | 2012-12-13 | 2013-12-13 | Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения |
Country Status (19)
Country | Link |
---|---|
US (2) | US9695212B2 (ru) |
EP (2) | EP3527579A1 (ru) |
JP (2) | JP6333843B2 (ru) |
KR (1) | KR20150095668A (ru) |
CN (2) | CN108542913A (ru) |
AU (2) | AU2013358892B2 (ru) |
BR (1) | BR112015013440B1 (ru) |
CA (1) | CA2886456A1 (ru) |
DK (1) | DK2931738T3 (ru) |
EA (1) | EA201590396A1 (ru) |
ES (1) | ES2718910T3 (ru) |
HK (1) | HK1212707A1 (ru) |
HU (1) | HUE043262T2 (ru) |
MX (1) | MX361680B (ru) |
PL (1) | PL2931738T3 (ru) |
PT (1) | PT2931738T (ru) |
SG (2) | SG11201502796RA (ru) |
SI (1) | SI2931738T1 (ru) |
WO (1) | WO2014093936A1 (ru) |
Families Citing this family (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3620185A1 (en) | 2010-10-06 | 2020-03-11 | President and Fellows of Harvard College | Injectable, pore-forming hydrogels for materials-based cell therapies |
JP6257607B2 (ja) | 2012-06-08 | 2018-01-10 | アデュロ バイオテック,インコーポレイテッド | 癌免疫療法のための組成物および方法 |
SI2931738T1 (sl) | 2012-12-13 | 2019-05-31 | Aduro Biotech, Inc. | Sestave, ki vsebujejo ciklične purin dinukleotide z definirano stereokemijo, ter metode za njihovo pripravo in uporabo |
BR112015014462A2 (pt) | 2012-12-19 | 2017-07-11 | Univ Texas | vetorização farmacêutica de uma via de sinalização de dinucleotídeos cíclicos de mamíferos |
AU2014260015B2 (en) | 2013-04-29 | 2019-11-14 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
CN105377867B (zh) * | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
DK2996473T3 (da) | 2013-05-18 | 2019-11-04 | Aduro Biotech Inc | Sammensætninger og fremgangsmåder til aktivering af "stimulator af interferon-gen"-afhængig signalering |
JP6400082B2 (ja) * | 2013-05-18 | 2018-10-03 | アデュロ バイオテック,インコーポレイテッド | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法 |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
WO2015017652A1 (en) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Sting crystals and modulators |
US20160287623A1 (en) * | 2013-11-19 | 2016-10-06 | The University Of Chicago | Use of sting agonist as cancer treatment |
CN103908468B (zh) * | 2014-04-21 | 2017-02-08 | 上海捌加壹医药科技有限公司 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
CN107073090A (zh) | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | 结合的疫苗装置和杀死癌细胞的方法 |
MX2016015928A (es) | 2014-06-04 | 2017-03-20 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos ciclicos como moduladores de sting. |
WO2016079899A1 (ja) * | 2014-11-20 | 2016-05-26 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 異なる核酸アジュバントの組み合わせによる、新規Th1誘導性アジュバントおよびその用途 |
PT3233882T (pt) | 2014-12-16 | 2020-01-21 | Kayla Therapeutics | Dinucleótidos cíclicos fluorados para a indução de citocinas |
GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
SG11201806623VA (en) | 2015-02-11 | 2018-09-27 | Univ Johns Hopkins | Bacteria over-expressing c-di-amp and therapeutic methods |
BR112017018908A2 (pt) * | 2015-03-10 | 2018-04-17 | Aduro Biotech, Inc. | composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon |
JP6786526B2 (ja) | 2015-06-03 | 2020-11-18 | ザ メディカル カレッジ オブ ウィスコンシン インクThe Medical College Of Wisconsin, Inc. | 改変されたccl20ロックド二量体ポリペプチド |
US11571462B2 (en) | 2015-06-03 | 2023-02-07 | The Medical College Of Wisconsin, Inc. | Engineered CCL20 locked dimer polypeptide |
US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
US10738074B2 (en) | 2015-08-13 | 2020-08-11 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as STING agonists |
PE20181322A1 (es) | 2015-09-01 | 2018-08-14 | Agenus Inc | Anticuerpo anti-pd1 y sus metodos de uso |
CN105367617A (zh) * | 2015-09-25 | 2016-03-02 | 武汉品生科技有限公司 | 一种基于环二腺核苷酸的衍生物、tat多肽及其在一型干扰素小分子中抑制剂的应用 |
MX2018005299A (es) * | 2015-10-28 | 2019-03-18 | Aduro Biotech Inc | Composiciones y métodos para activar la señalización dependiente del "estimulador del gen de interferon". |
CN106539813B (zh) * | 2015-11-30 | 2019-12-03 | 杭州星鳌生物科技有限公司 | 干扰素刺激基因(sting)激活剂在抗炎症中的应用 |
KR101949108B1 (ko) | 2015-12-03 | 2019-02-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Sting의 조정제로서의 시클릭 푸린 디뉴클레오티드 |
CN106554416B (zh) * | 2015-12-09 | 2019-03-15 | 聊城市奥润生物医药科技有限公司 | 一种抗pd-l1人源化单克隆抗体联合干扰素基因刺激蛋白(sting)激动剂在抗肿瘤中的应用 |
CN106540260A (zh) * | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 干扰素基因刺激蛋白(sting)激动剂在抗阿尔兹海默症中的应用 |
CN106539814A (zh) * | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 干扰素基因刺激蛋白(sting)激动剂在抗类风湿性关节炎等疾病中的应用 |
IL259931B2 (en) | 2015-12-16 | 2024-02-01 | Gritstone Bio Inc | Identification of neo-antigens, preparation, and use |
US20180369268A1 (en) * | 2015-12-16 | 2018-12-27 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production |
EA036421B1 (ru) | 2016-01-11 | 2020-11-09 | Иннэйт Тьюмор Иммьюнити, Инк. | Соединения и композиции для лечения состояний, ассоциированных с активностью sting |
CN109069440A (zh) * | 2016-03-02 | 2018-12-21 | 得克萨斯州大学系统董事会 | 用于免疫治疗的激活sting的纳米疫苗 |
PT3429596T (pt) | 2016-03-18 | 2022-11-25 | Immune Sensor Llc | Compostos de dinucleotídeos cíclicos e métodos de utilização |
CN106539757A (zh) * | 2016-03-20 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP-脂质体在抗肿瘤中的应用 |
SI3440076T1 (sl) | 2016-04-07 | 2022-09-30 | Glaxosmithkline Intellectual Property Development Limited | Heterociklični amidi uporabni kot proteinski modulatorji |
CN109563081A (zh) | 2016-04-07 | 2019-04-02 | 葛兰素史克知识产权开发有限公司 | 可用作蛋白调节剂的杂环酰胺类 |
WO2017186711A1 (en) | 2016-04-25 | 2017-11-02 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
US10696985B1 (en) | 2016-06-06 | 2020-06-30 | Vanderbilt University | Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery |
EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
EP3481402A4 (en) | 2016-07-06 | 2020-01-22 | Sperovie Biosciences, Inc. | CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE |
WO2018013924A1 (en) | 2016-07-15 | 2018-01-18 | Massachusetts Institute Of Technology | Synthetic nanoparticles for delivery of immunomodulatory compounds |
DE102016113714A1 (de) | 2016-07-26 | 2018-02-01 | Rosa Karl | Transfektionsverfahren mit nicht-viralen Genliefersystemen |
NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
AU2017321609C1 (en) | 2016-08-30 | 2023-11-09 | Dana-Farber Cancer Institute, Inc. | Drug delivery compositions and uses thereof |
US11052149B2 (en) | 2016-09-19 | 2021-07-06 | The University Of North Carolina At Chapel Hill | Methods and compositions for inducing an immune response |
US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
SI3523287T1 (sl) | 2016-10-04 | 2021-11-30 | Merck Sharp & Dohme Corp. | Benzo(b)tiofenske spojine kot agonisti STING |
US10266558B2 (en) * | 2016-10-07 | 2019-04-23 | Alexandre Vasilievich Ivachtchenko | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof |
EP3523314A1 (de) | 2016-10-07 | 2019-08-14 | Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb GmbH | Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen |
JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
WO2018119117A1 (en) * | 2016-12-22 | 2018-06-28 | The Regents Of The University Of California | Methods of producing cyclic dinucleotides |
JP2018131427A (ja) * | 2017-02-17 | 2018-08-23 | 国立研究開発法人理化学研究所 | 免疫細胞の制御技術 |
US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
WO2018156625A1 (en) | 2017-02-21 | 2018-08-30 | Board Of Regents,The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
CN106928298B (zh) * | 2017-03-13 | 2021-10-22 | 杭州星鳌生物科技有限公司 | 环二核苷酸cGAMP衍生物的结构组成、制备方法及其在抗肿瘤中的应用 |
JOP20190218A1 (ar) * | 2017-03-22 | 2019-09-22 | Boehringer Ingelheim Int | مركبات ثنائية النيوكليوتيدات حلقية معدلة |
JP7160833B2 (ja) | 2017-04-13 | 2022-10-25 | サイロパ ビー.ブイ. | 抗sirpアルファ抗体 |
EP3610022A1 (en) | 2017-04-14 | 2020-02-19 | Tollnine, Inc. | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
WO2018208667A1 (en) | 2017-05-12 | 2018-11-15 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
MA49772A (fr) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme | Agonistes benzo[b]thiophène de sting pour le traitement du cancer |
JP2020529421A (ja) | 2017-08-04 | 2020-10-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | がんの処置のためのPD−1アンタゴニストおよびベンゾ[b]チオフェンSTINGアゴニストの組み合わせ |
EP3692048A4 (en) | 2017-08-30 | 2021-10-20 | Beijing Xuanyi Pharmasciences Co., Ltd. | CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS |
EP3675859A4 (en) | 2017-08-31 | 2021-06-30 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES |
WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
WO2019051489A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
US20200230221A1 (en) | 2017-09-19 | 2020-07-23 | Massachusetts Institute Of Technology | Compositions for chimeric antigen receptor t cell therapy and uses thereof |
WO2019069270A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | GENERATOR STIMULATOR MODULATORS (STING) INTERFERON |
EP3692033A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
CN111465989A (zh) | 2017-10-10 | 2020-07-28 | 磨石肿瘤生物技术公司 | 使用热点进行的新抗原鉴别 |
JP7195317B2 (ja) | 2017-11-10 | 2022-12-23 | 武田薬品工業株式会社 | Sting調節剤化合物、ならびに製造及び使用する方法 |
CN111587114A (zh) * | 2017-11-14 | 2020-08-25 | 儿童医学中心公司 | 用于调节人免疫应答的咪唑并嘧啶的用途 |
US11673891B2 (en) | 2017-11-14 | 2023-06-13 | Dana-Farber Cancer Institute, Inc. | Imidazopyrimidine compounds and uses thereof |
JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
US11685761B2 (en) | 2017-12-20 | 2023-06-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
CA3084582A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
WO2019161171A1 (en) * | 2018-02-16 | 2019-08-22 | Sperovie Biosciences, Inc. | Nanoparticle formulations of sting agonists |
BR112020019089A2 (pt) | 2018-03-23 | 2020-12-29 | Codiak Biosciences, Inc. | Vesículas extracelulares compreendendo agonista de sting |
CN111971291A (zh) | 2018-03-27 | 2020-11-20 | 勃林格殷格翰国际有限公司 | 用作sting激动剂的含有2-氮杂-次黄嘌呤或6h-吡唑并[1,5-d][1,2,4]三嗪-7-酮的环状二核苷酸化合物 |
US20210024567A1 (en) | 2018-03-27 | 2021-01-28 | Boehringer Ingelheim International Gmbh | Modified cyclic dinucleotide compounds |
US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
MX2020010407A (es) | 2018-04-03 | 2020-10-22 | Merck Sharp & Dohme | Benzotiofenos y compuestos relacionados como agonistas de sting. |
WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
CN111954675A (zh) | 2018-04-06 | 2020-11-17 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
EP3802534B1 (en) | 2018-05-25 | 2022-07-13 | Incyte Corporation | Tricyclic heterocyclic compounds as sting activators |
KR20210015937A (ko) | 2018-06-01 | 2021-02-10 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 방광암을 치료하기 위한 방법 |
US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
US11008344B2 (en) | 2018-07-31 | 2021-05-18 | Incyte Corporation | Tricyclic heteroaryl compounds as STING activators |
CA3107263A1 (en) * | 2018-08-03 | 2020-02-06 | The University Of Tokyo | Nasal vaccine that induces cell-mediated immunity |
BR112021001349A2 (pt) | 2018-08-16 | 2021-04-20 | Eisai R&D Management Co., Ltd. | sais de compostos e cristais dos mesmos |
JP7254818B2 (ja) | 2018-09-06 | 2023-04-10 | 第一三共株式会社 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
WO2020059895A1 (ko) * | 2018-09-17 | 2020-03-26 | 주식회사 큐라티스 | 스팅 작용자를 포함하는 면역항원보강제 및 백신 조성물 |
AU2019344398B2 (en) | 2018-09-21 | 2022-09-22 | Shanghai De Novo Pharmatech Co., Ltd. | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application |
US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
EP3873484B1 (en) | 2018-10-29 | 2023-08-23 | Venenum Biodesign, LLC | Novel sting agonists |
WO2020092633A1 (en) | 2018-10-30 | 2020-05-07 | Vanderbilt University | Graft copolymers, methods of forming graft copolymers, and methods of use thereof |
WO2020092617A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody conjugates comprising sting agonists |
US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
JP7224688B2 (ja) * | 2019-01-10 | 2023-02-20 | 南▲開▼大学 | 環状ジヌクレオチドプロドラッグ分子、その製造方法及び使用 |
KR20210137518A (ko) | 2019-03-07 | 2021-11-17 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
CN113543851A (zh) | 2019-03-07 | 2021-10-22 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
US20240108747A1 (en) | 2019-03-21 | 2024-04-04 | Lonza Sales Ag | Extracellular vesicle conjugates and uses thereof |
KR20220004035A (ko) | 2019-03-21 | 2022-01-11 | 코디악 바이오사이언시즈, 인크. | 백신 전달을 위한 세포외 소포 |
EP3941607A1 (en) | 2019-03-21 | 2022-01-26 | Codiak BioSciences, Inc. | Process for preparing extracellular vesicles |
US20220177465A1 (en) | 2019-04-04 | 2022-06-09 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes |
TW202104214A (zh) | 2019-04-05 | 2021-02-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
MA55805A (fr) * | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
EP3966222A4 (en) | 2019-05-09 | 2023-10-04 | Aligos Therapeutics, Inc. | MODIFIED CYCLIC DI-NUCLEOSIDE COMPOUNDS AS STING MODULATORS |
CA3139809A1 (en) | 2019-05-10 | 2020-11-19 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
US20220251200A1 (en) | 2019-07-03 | 2022-08-11 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
US20230181758A1 (en) | 2019-07-03 | 2023-06-15 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
KR20220056176A (ko) | 2019-08-02 | 2022-05-04 | 메르사나 테라퓨틱스, 인코포레이티드 | 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물 |
EP4013788A1 (en) | 2019-08-12 | 2022-06-22 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
EP3785719A1 (en) * | 2019-08-28 | 2021-03-03 | Helmholtz-Zentrum für Infektionsforschung GmbH | New use of cyclic dinucleotides |
WO2021062058A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
EP4034081A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Extracellular vesicle compositions |
US20230103726A1 (en) | 2019-09-25 | 2023-04-06 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
JP2022551420A (ja) | 2019-09-25 | 2022-12-09 | コディアック バイオサイエンシーズ, インコーポレイテッド | 腫瘍を治療するためのil-12提示エクソソームとstingアゴニスト含有エクソソームとの併用 |
TW202128775A (zh) | 2019-10-16 | 2021-08-01 | 英商阿法克塔生命科學有限公司 | PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分 |
WO2021113679A1 (en) | 2019-12-06 | 2021-06-10 | Mersana Therapeutics, Inc. | Dimeric compounds as sting agonists |
AU2020407871A1 (en) | 2019-12-20 | 2022-06-30 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
AU2021226023A1 (en) | 2020-02-28 | 2022-09-15 | Tallac Therapeutics, Inc. | Transglutaminase-mediated conjugation |
CN115209921A (zh) | 2020-03-06 | 2022-10-18 | 第一三共株式会社 | 包含新型环状二核苷酸衍生物的抗体药物偶联物 |
US20230114434A1 (en) | 2020-03-13 | 2023-04-13 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
AU2021236763A1 (en) | 2020-03-20 | 2022-10-06 | Lonza Sales Ag | Extracellular vesicles for therapy |
WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
US20230149560A1 (en) | 2020-04-20 | 2023-05-18 | Massachusetts Institute Of Technology | Lipid compositions for delivery of sting agonist compounds and uses thereof |
WO2021221782A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
WO2021221783A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
EP4149424A1 (en) | 2020-05-13 | 2023-03-22 | Massachusetts Institute Of Technology | Compositions of polymeric microdevices and their use in cancer immunotherapy |
WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
CN116113641A (zh) | 2020-09-02 | 2023-05-12 | 第一三共株式会社 | 新型内-β-N-乙酰氨基葡萄糖苷酶 |
EP4217087A2 (en) | 2020-09-23 | 2023-08-02 | Codiak BioSciences, Inc. | Process for preparing extracellular vesicles |
WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
EP4216993A2 (en) | 2020-09-23 | 2023-08-02 | Codiak BioSciences, Inc. | Methods of producing extracellular vesicles |
WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
US20220111028A1 (en) | 2020-10-14 | 2022-04-14 | Boehringer Ingelheim International Gmbh | Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist |
TW202227099A (zh) * | 2020-10-20 | 2022-07-16 | 大陸商泰勵生物科技(上海)有限公司 | 多功能環二核苷酸及其用途 |
IL302390A (en) | 2020-11-09 | 2023-06-01 | Takeda Pharmaceuticals Co | Drug antibody conjugates |
EP4262878A1 (en) | 2020-12-17 | 2023-10-25 | Trustees Of Tufts College | Fap-activated radiotheranostics, and uses related thereto |
EP4032545A1 (en) * | 2021-01-26 | 2022-07-27 | Medizinische Hochschule Hannover | Immunogenic composition and vaccine containing chlamydia ssp. surface antigens and its use |
WO2022223619A1 (en) | 2021-04-20 | 2022-10-27 | Institut Curie | Compositions and methods for use in immunotherapy |
WO2022223622A1 (en) | 2021-04-20 | 2022-10-27 | Institut Curie | Compositions and methods for use in immunotherapy |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
WO2023056468A1 (en) | 2021-09-30 | 2023-04-06 | Codiak Biosciences, Inc. | Extracellular vesicle comprising cholesterol tagged sting-agonist |
WO2023057567A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
WO2023168112A1 (en) | 2022-03-04 | 2023-09-07 | Massachusetts Institute Of Technology | Transmucosal amphiphile-protein conjugate vaccine |
WO2023218243A1 (en) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Lag-3/pd-l1 binding fusion proteins |
WO2024036275A1 (en) * | 2022-08-10 | 2024-02-15 | Aldevron Llc | Methods for producing cyclic dinucleotides |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9110808D0 (en) | 1991-05-17 | 1991-07-10 | Retroscreen Ltd | Aids vaccine and method for its production |
GB2257704B (en) * | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
US5637483A (en) | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
US5904920A (en) | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
IT1262895B (it) | 1992-03-02 | 1996-07-22 | Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico. | |
US5635160A (en) | 1995-06-07 | 1997-06-03 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions |
US6033674A (en) | 1995-12-28 | 2000-03-07 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
AU741602B2 (en) | 1998-02-02 | 2001-12-06 | Johns Hopkins University School Of Medicine, The | A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use |
DE60021354T2 (de) | 1999-02-15 | 2006-04-27 | Nippon Shinyaku Co., Ltd. | Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung |
US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
EP1320602A2 (en) | 2000-09-21 | 2003-06-25 | The Regents Of The University Of California | Spas-1 cancer antigen |
EP1326638B9 (en) | 2000-10-18 | 2008-02-20 | GlaxoSmithKline Biologicals S.A. | Vaccines against cancers |
US7279883B2 (en) | 2001-01-23 | 2007-10-09 | Lydia L. Sohn | Particle analyzer and methods for use thereof |
TW200303759A (en) | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
WO2005030186A2 (en) | 2003-07-28 | 2005-04-07 | Univ Maryland | Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation |
JP2007509067A (ja) | 2003-10-15 | 2007-04-12 | メディミューン,インコーポレーテッド | リステリアに基づくEphA2ワクチン |
JP2007533647A (ja) * | 2003-10-24 | 2007-11-22 | アルザ・コーポレーシヨン | 脂質粒子の調製 |
US7709458B2 (en) | 2004-03-15 | 2010-05-04 | David K. R. Karaolis | Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
US7592326B2 (en) * | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
EP1888790A2 (en) | 2005-05-06 | 2008-02-20 | The Regents of the University of California | Microfluidic system for identifying or sizing individual particles passing through a channel |
US20070059683A1 (en) | 2005-09-15 | 2007-03-15 | Tom Barber | Veterinary diagnostic system |
EP1782826A1 (en) * | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
CA2631931C (en) | 2005-12-01 | 2014-04-29 | Pronai Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
WO2008016473A2 (en) | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
CA2662335A1 (en) | 2006-09-05 | 2008-03-13 | Valeria Ossovskaya | Methods for designing parp inhibitors and uses thereof |
TWI444384B (zh) * | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
JP2011529708A (ja) | 2008-08-04 | 2011-12-15 | ユニバーシティ オブ マイアミ | 自然免疫応答の調節因子sting(インターフェロン遺伝子の刺激因子) |
US8840881B2 (en) | 2008-08-28 | 2014-09-23 | Aduro Gvax Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
AU2009325926B2 (en) * | 2008-12-09 | 2013-05-16 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
ES2593862T3 (es) | 2009-03-09 | 2016-12-13 | Molecular Express, Inc. | Métodos y composiciones de formulación liposomal de antígenos y usos de los mismos |
US8414630B2 (en) | 2009-03-10 | 2013-04-09 | Marc Evan Richelsoph | Active bone screw |
AU2010256461B2 (en) | 2009-06-05 | 2016-03-17 | Access To Advanced Health Institute | Synthetic glucopyranosyl lipid adjuvants |
WO2011003025A1 (en) | 2009-07-01 | 2011-01-06 | Rutgers, The State University Of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
US8771933B2 (en) | 2009-10-06 | 2014-07-08 | Massachusetts Institute Of Technology | Continuous-flow deformability-based cell separation |
EP3000885B1 (en) * | 2009-12-18 | 2018-07-25 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
EP2361911A1 (en) * | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
US20120064505A1 (en) | 2010-03-22 | 2012-03-15 | Massachusetts Institute Of Technology | Measurement of material properties and related methods and compositions |
CN102199183B (zh) | 2010-03-26 | 2013-12-18 | 北京大学 | 环二鸟苷酸及其类似物和制备方法 |
BR112012027745A2 (pt) | 2010-04-27 | 2017-01-10 | Univ Johns Hopkins | método e composição imunogênica para tratamento de neoplásia |
US8450293B2 (en) | 2010-08-10 | 2013-05-28 | Rutgers, The State University Of New Jersey | Synthesis and characterization of C8 analogs of c-di-GMP |
PL2640842T3 (pl) | 2010-11-17 | 2018-11-30 | Aduro Biotech, Inc. | Sposoby i kompozycje do indukowania odpowiedzi immunologicznej na EGFRVIII |
US9061048B2 (en) | 2010-12-15 | 2015-06-23 | The Regents Of The University Of California | Cyclic di-AMP induction of type I interferon |
WO2012088155A1 (en) | 2010-12-22 | 2012-06-28 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
JP5990256B2 (ja) | 2011-04-15 | 2016-09-07 | ザ ユニバーシティ オブ ブリティッシュ コロンビアThe University Of British Columbia | 粒子分離の方法および装置 |
WO2013086331A1 (en) | 2011-12-07 | 2013-06-13 | President And Fellows Of Harvard College | High efficiency di-nucleotide cyclase |
AU2013256468A1 (en) | 2012-04-30 | 2014-12-04 | Glen N. Barber | Modulating immune responses |
JP6257607B2 (ja) | 2012-06-08 | 2018-01-10 | アデュロ バイオテック,インコーポレイテッド | 癌免疫療法のための組成物および方法 |
CN112587671A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
US9090646B2 (en) | 2012-12-05 | 2015-07-28 | Rutgers, The State University Of New Jersey | Biotinylated compounds |
SI2931738T1 (sl) | 2012-12-13 | 2019-05-31 | Aduro Biotech, Inc. | Sestave, ki vsebujejo ciklične purin dinukleotide z definirano stereokemijo, ter metode za njihovo pripravo in uporabo |
BR112015014462A2 (pt) | 2012-12-19 | 2017-07-11 | Univ Texas | vetorização farmacêutica de uma via de sinalização de dinucleotídeos cíclicos de mamíferos |
AU2014260015B2 (en) | 2013-04-29 | 2019-11-14 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
DK2996473T3 (da) | 2013-05-18 | 2019-11-04 | Aduro Biotech Inc | Sammensætninger og fremgangsmåder til aktivering af "stimulator af interferon-gen"-afhængig signalering |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
JP6400082B2 (ja) | 2013-05-18 | 2018-10-03 | アデュロ バイオテック,インコーポレイテッド | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法 |
WO2015017652A1 (en) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Sting crystals and modulators |
JP2016535731A (ja) | 2013-10-21 | 2016-11-17 | ドレクセル ユニバーシティ | 慢性b型肝炎ウイルス感染を処置するためのstingアゴニストの使用 |
US20160287623A1 (en) | 2013-11-19 | 2016-10-06 | The University Of Chicago | Use of sting agonist as cancer treatment |
EP3071229A4 (en) | 2013-11-22 | 2017-05-10 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
WO2015085565A1 (en) | 2013-12-13 | 2015-06-18 | Qualcomm Incorporated | Methods and apparatus for cell selection in a wireless communication system |
WO2015108595A1 (en) | 2014-01-15 | 2015-07-23 | Nikolai Khodarev | Anti-tumor therapy |
MX2016015928A (es) | 2014-06-04 | 2017-03-20 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos ciclicos como moduladores de sting. |
PT3233882T (pt) | 2014-12-16 | 2020-01-21 | Kayla Therapeutics | Dinucleótidos cíclicos fluorados para a indução de citocinas |
GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
BR112017018908A2 (pt) * | 2015-03-10 | 2018-04-17 | Aduro Biotech, Inc. | composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon |
US10738074B2 (en) | 2015-08-13 | 2020-08-11 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as STING agonists |
KR101949108B1 (ko) | 2015-12-03 | 2019-02-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Sting의 조정제로서의 시클릭 푸린 디뉴클레오티드 |
-
2013
- 2013-12-13 SI SI201331392T patent/SI2931738T1/sl unknown
- 2013-12-13 CN CN201810801443.9A patent/CN108542913A/zh active Pending
- 2013-12-13 US US14/106,687 patent/US9695212B2/en active Active
- 2013-12-13 DK DK13863379.7T patent/DK2931738T3/en active
- 2013-12-13 PL PL13863379T patent/PL2931738T3/pl unknown
- 2013-12-13 HU HUE13863379A patent/HUE043262T2/hu unknown
- 2013-12-13 MX MX2015007447A patent/MX361680B/es active IP Right Grant
- 2013-12-13 CA CA2886456A patent/CA2886456A1/en not_active Abandoned
- 2013-12-13 JP JP2015548023A patent/JP6333843B2/ja not_active Expired - Fee Related
- 2013-12-13 EA EA201590396A patent/EA201590396A1/ru unknown
- 2013-12-13 ES ES13863379T patent/ES2718910T3/es active Active
- 2013-12-13 SG SG11201502796RA patent/SG11201502796RA/en unknown
- 2013-12-13 AU AU2013358892A patent/AU2013358892B2/en not_active Ceased
- 2013-12-13 BR BR112015013440-8A patent/BR112015013440B1/pt not_active IP Right Cessation
- 2013-12-13 WO PCT/US2013/075189 patent/WO2014093936A1/en active Application Filing
- 2013-12-13 PT PT13863379T patent/PT2931738T/pt unknown
- 2013-12-13 EP EP19151113.8A patent/EP3527579A1/en not_active Withdrawn
- 2013-12-13 CN CN201380065216.XA patent/CN105008381B/zh active Active
- 2013-12-13 EP EP13863379.7A patent/EP2931738B1/en active Active
- 2013-12-13 SG SG10201704611WA patent/SG10201704611WA/en unknown
- 2013-12-13 KR KR1020157015489A patent/KR20150095668A/ko active IP Right Grant
-
2016
- 2016-01-21 HK HK16100666.5A patent/HK1212707A1/zh not_active IP Right Cessation
-
2017
- 2017-06-22 US US15/630,741 patent/US10414789B2/en active Active
-
2018
- 2018-04-25 JP JP2018084405A patent/JP6704012B2/ja active Active
- 2018-05-25 AU AU2018203682A patent/AU2018203682B2/en not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201590396A1 (ru) | Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения | |
EA201791999A1 (ru) | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" | |
PH12015502438A1 (en) | Compositions and methods for activating ``stimulator of interferon gene``-dependent signalling | |
EA201790781A3 (ru) | Противовирусные соединения | |
EA201891264A3 (ru) | Антагонисты st2l и способы их применения | |
EA201790963A1 (ru) | Противовирусные соединения | |
EA202190619A1 (ru) | Противовирусные соединения | |
MX2016002571A (es) | Regulador de ph de transduccion. | |
EA201491579A1 (ru) | Соединения оксазолидин-2-она и их применения в качестве ингибиторов pi3k | |
EA201790461A1 (ru) | Композиции внеклеточного матрикса | |
EA201490037A1 (ru) | Антагонисты trpv4 | |
EA201591380A1 (ru) | АНТАГОНИСТЫ Kv1.3 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
IN2015DN02912A (ru) | ||
EA201890434A1 (ru) | Антитела к cd154 и способы их применения | |
EA201592056A1 (ru) | Высококонцентрированные составы растворимых fc-рецепторов | |
TN2015000408A1 (en) | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling | |
EA201592204A1 (ru) | Композиции и способы для активации передачи сигналов, зависящей от "стимулятора гена интерферона" |